Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Disturbed intracellular calcium (Ca 2+) homeostasis has been implicated in bipolar disorder (BD). Reduced mRNA levels of the transient receptor potential Ca 2+ permeable channel melastatin type 2, TRPM2, in B lymphoblast cell lines (BLCL) from bipolar I disorder (BD‐I) patients showing elevated basal intracellular Ca 2+ ([Ca 2+]B), an index of altered intracellular Ca 2+ homeostasis, along with its location within a putative BD susceptibility locus (21q22.3), implicates the involvement of this gene in the Ca 2+ abnormalities and the genetic diathesis to BD. We tested this hypothesis by examining the association of selected single nucleotide polymorphisms (SNPs) and their haplotypes, spanning the TRPM2 gene, with BD and BLCL [Ca 2+]B, in a case control design. The 5′ TaqMan SNP assay was used to detect selected SNPs. BLCL [Ca 2+]B was determined by ratiometric fluorometry. SNP rs1618355 in intron 18 was significantly associated with BD as a whole (P < 7.0 × 10−5; odds ratio (OR) = 2.60), and when stratified into BD‐I (P < 7.0 × 10−5, OR = 2.48) and BD‐II (P = 7.0 × 10−5, OR = 2.88) subgroups. In addition, the alleles of the individual SNPs forming a seven marker at‐risk haplotype were in excess in BD (12.0% in BD vs. 0.9% in controls; P = 2.3 × 10−12). A weak relationship was also detected between BLCL [Ca 2+]B and TRPM2 SNP rs1612472 in intron 19. These findings suggest genetic variants of the TRPM2 gene increase risk for BD and support the notion that TRPM2 may be involved in the pathophysiology of BD. © 2005 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Haplotype Blocks in the Human Genome
Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., et al. (2002) · Science · doi:10.1126/science.1069424 · Cited by 5,863 · cited 3×
“…has been used to successfully map mutations associated with complex diseases [Tishkoff and Verrelli, 2003] as it affords the advantage of being able to test associations between genomic segments encoding multiple genes and traits [Gabriel et al., 2002], in contrast to individual polymorphisms.”
BackgroundMethodInfluentialRNA regulation: A new genetics?
Mattick, J. S. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1321 · Cited by 765 · cited 1×
“Furthermore, thepotential for regulation of gene expression by intronic transcribed noncoding RNAs has recently been recognized [Mattick, 2004].”
Background
Cited by
Venkatachalam, K., & Montell, C. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142819 · Cited by 1,909
Transient Receptor Potential Cation Channels in Disease
Nilius, B., Owsianik, G., Voets, T., & Peters, J. A. (2007) · Physiological Reviews · doi:10.1152/physrev.00021.2006 · Cited by 1,399
Advances in TRP channel drug discovery: from target validation to clinical studies
Koivisto, A.-P., Belvisi, M. G., Gaudet, R., & Szallasi, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00268-4 · Cited by 537
Zhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Nilius, B., & Szallasi, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008268 · Cited by 506
Metadata
- Authors
- Xu, C., Macciardi, F., Li, P. P., Yoon, I., Cooke, R. G., Hughes, B., Parikh, S. V., McIntyre, R. S., Kennedy, J. L., & Warsh, J. J.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2005-10-26
- Volume
- 141B
- Issue
- 1
- Pages
- 36-43
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2028541149
- Cited by
- 98
- References
- 2
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.